266 related articles for article (PubMed ID: 1562539)
1. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
Veldscholte J; Berrevoets CA; Ris-Stalpers C; Kuiper GG; Jenster G; Trapman J; Brinkmann AO; Mulder E
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):665-9. PubMed ID: 1562539
[TBL] [Abstract][Full Text] [Related]
2. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.
Veldscholte J; Ris-Stalpers C; Kuiper GG; Jenster G; Berrevoets C; Claassen E; van Rooij HC; Trapman J; Brinkmann AO; Mulder E
Biochem Biophys Res Commun; 1990 Dec; 173(2):534-40. PubMed ID: 2260966
[TBL] [Abstract][Full Text] [Related]
3. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation.
Veldscholte J; Berrevoets CA; Brinkmann AO; Grootegoed JA; Mulder E
Biochemistry; 1992 Mar; 31(8):2393-9. PubMed ID: 1540595
[TBL] [Abstract][Full Text] [Related]
4. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1991; 40(1-3):193-7. PubMed ID: 1958520
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
6. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP.
Montgomery BT; Young CY; Bilhartz DL; Andrews PE; Prescott JL; Thompson NF; Tindall DJ
Prostate; 1992; 21(1):63-73. PubMed ID: 1379363
[TBL] [Abstract][Full Text] [Related]
7. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor.
Grigoryev DN; Long BJ; Njar VC; Brodie AH
J Steroid Biochem Mol Biol; 2000 Dec; 75(1):1-10. PubMed ID: 11179903
[TBL] [Abstract][Full Text] [Related]
8. Studies on the human prostatic cancer cell line LNCaP.
Veldscholte J; Berrevoets CA; Mulder E
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):341-6. PubMed ID: 8043498
[TBL] [Abstract][Full Text] [Related]
9. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation.
Kokontis J; Ito K; Hiipakka RA; Liao S
Receptor; 1991; 1(4):271-9. PubMed ID: 1668832
[TBL] [Abstract][Full Text] [Related]
10. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids.
Veldscholte J; Voorhorst-Ogink MM; Bolt-de Vries J; van Rooij HC; Trapman J; Mulder E
Biochim Biophys Acta; 1990 Apr; 1052(1):187-94. PubMed ID: 2322591
[TBL] [Abstract][Full Text] [Related]
11. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):849-53. PubMed ID: 2149505
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
14. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects.
Térouanne B; Tahiri B; Georget V; Belon C; Poujol N; Avances C; Orio F; Balaguer P; Sultan C
Mol Cell Endocrinol; 2000 Feb; 160(1-2):39-49. PubMed ID: 10715537
[TBL] [Abstract][Full Text] [Related]
15. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element.
Riegman PH; Vlietstra RJ; van der Korput JA; Brinkmann AO; Trapman J
Mol Endocrinol; 1991 Dec; 5(12):1921-30. PubMed ID: 1724287
[TBL] [Abstract][Full Text] [Related]
16. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
[TBL] [Abstract][Full Text] [Related]
17. Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line.
Guillemette C; Hum DW; Bélanger A
Endocrinology; 1996 Jul; 137(7):2872-9. PubMed ID: 8770908
[TBL] [Abstract][Full Text] [Related]
18. Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity.
Ris-Stalpers C; Verleun-Mooijman MC; Trapman J; Brinkmann AO
Biochem Biophys Res Commun; 1993 Oct; 196(1):173-80. PubMed ID: 8216289
[TBL] [Abstract][Full Text] [Related]
19. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens.
Kuil CW; Mulder E
Endocrinology; 1996 May; 137(5):1870-7. PubMed ID: 8612526
[TBL] [Abstract][Full Text] [Related]
20. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
